Johnson & Johnson (JNJ) has been quietly crushing its major peer in terms of stock performance - Procter & Gamble (PG), which has an activist investor. Johnson & Johnson shares are up 17%, while P&G is up just 6%.
Johnson & Johnson, unlike P&G, is a bigger play on the healthcare market. As well, I think Johnson & Johnson has more clear catalysts than the likes of P&G. For one, a major buyout might work well for Johnson & Johnson, which includes buying up Colgate-Palmolive (CL) - the $67 billion market cap consumer products company.
This comes as Johnson & Johnson's estimates have missed a few times of late. It just goes to show how hard it is for a company that’s $370 billion in market cap.
